PD-L1 inhibitor plus chemo improves PFS.

THERAPEUTIC use of monoclonal antibodies; PLATINUM compounds; ANTINEOPLASTIC agents; BLADDER tumors; CANCER chemotherapy; COMBINED modality therapy; IMMUNOTHERAPY; METASTASIS; SURVIVAL; TUMOR classification; TREATMENT effectiveness; DISEASE progression; THERAPEUTICS

The article discusses a 2019 study which shows that the combination of immunotherapy atezolizumab (Tencentriq) and platinum-based chemotherapy improved progression-free survival of patients with previously untreated metastatic urothelial carcinoma compared to chemotherapy alone. It states that this expands immunotherapy use in a broader group of patients and that it has potential of becoming standard of care in these patients. Also noted is atezolizumab's approval for advanced bladder cancer.